Considering that half of pancreatic cancers and more than 20% of colon cancers show deletion of Smad4 [12–14], inhibition of PAK1 would be one of plausible strategy for treatment of human cancers such as pancreatic cancer and colon cancer. Here, PAK1 is linked to cancer.